Results 141 to 150 of about 3,797 (192)

Hepatitis C in the Direct-Acting Antiviral Era: Immunopathogenesis, Dendritic Cells and Modern Clinical Management. [PDF]

Biomedicines
Kurmangaliyeva K, Kosherova B, Mukatova I, Baibusunova A, Yeshmagambetova Z, Askarova K, Kazangapova A, Shlymova R.   +7 more
europepmc   +1 more source

Cyclosporine A sterically inhibits statin transport by solute carrier OATP1B1. [PDF]

J Biol Chem
Sung MW, Hu K, Hurlimann LM, Lees JA, Fennell KF, West MA, Costales C, Rodrigues AD, Zimmermann I, Dawson RJP, Liu S, Han S.   +11 more
europepmc   +1 more source

Hepatitis C Direct-Acting Antivirals in the Immunosuppressed Host: Mechanisms, Interactions, and Clinical Outcomes. [PDF]

Viruses
AlKaabi H, AlSinani S, El-Kassas M, Alswat KA, AlNaamani KM.   +4 more
europepmc   +1 more source

Are Direct-Acting Antivirals Effective and Safe for Hepatitis C Patients with Arterial Hypertension? Evidence from a Large Retrospective Real-World Study. [PDF]

Viruses
Brzdęk M, Rzymski P, Zarębska-Michaluk D, Poniedziałek B, Lorenc B, Berak H, Mazur W, Janocha-Litwin J, Tudrujek-Zdunek M, Sitko M, Klapaczyński J, Flisiak R.   +11 more
europepmc   +1 more source

Single-cell profiling of SLC family transporters: uncovering the role of SLC7A1 in osteosarcoma. [PDF]

J Transl Med
Liao Y, Chen J, Yao H, Zheng T, Tu J, Chen W, Guo Z, Zou Y, Wen L, Xie X.   +9 more
europepmc   +1 more source

Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen [PDF]

Antimicrobial Agents and Chemotherapy, 2017
Interactions between simeprevir (hepatitis C virus [HCV] NS3/4A protease inhibitor) and ledipasvir (HCV NS5A replication complex inhibitor) were investigated in treatment-naive HCV genotype 1-infected patients without cirrhosis, treated with simeprevir ...
Veerle van Eygen, Sivi Ouwerkerk-Mahadevan, Frederik Nevens   +2 more
exaly   +2 more sources

Unexpected Replication Boost by Simeprevir for Simeprevir-Resistant Variants in Genotype 1a Hepatitis C Virus

Antimicrobial Agents and Chemotherapy, 2018
Simeprevir is a novel NS3/4A protease inhibitor (PI) of hepatitis C virus (HCV). The baseline polymorphism NS3-Q80K is frequently observed in genotype (GT) 1a HCV and often associated with treatment failure in simeprevir-containing regimens.
Shuichi Kaneko, Christoph Welsch, Tetsuro Shimakami   +2 more
exaly   +2 more sources

Development of a simple HPLC–UV method for the determination of the hepatitis C virus inhibitor simeprevir in human plasma [PDF]

Journal of Pharmaceutical and Biomedical Analysis, 2016
A simple high-performance liquid chromatography method for the determination of the hepatitis C virus protease inhibitor simeprevir in human plasma was developed and validated.
Alfredo Alberti, Giorgio Palu, Saverio Parisi   +2 more
exaly   +2 more sources

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies [PDF]

Journal of Hepatology, 2015
Background & AimsSimeprevir is an oral hepatitis C virus (HCV) NS3/4A protease inhibitor approved for treatment of chronic HCV infection. Baseline NS3 polymorphisms in all patients and emerging mutations in patients who failed to achieve sustained ...
Thierry Verbinnen, Leen Vijgen, Hugo Ceulemans   +2 more
exaly   +2 more sources